To test our hypothesis that syndecan-4 could constitute a blood biomarker of cardiac inflammation, syndecan-4 was measured by ELISA in serum samples from a total of 549 well-characterized patients with cardiomyopathies of various etiologies and stages of disease, or acute MI. Here, SDC4 is linked to cardiomyopathy.